Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Spectrochim Acta A Mol Biomol Spectrosc ; 316: 124372, 2024 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-38703408

RESUMEN

Here, a novel fluorescence strategy was established for the detection of mirabegron (MBG) sensitively on the basis of hantzsch dihydropyridine synthesis. The developed method adopts turn-on fluorescence of MBG for the first time, permitting its selective determination in spiked human plasma at 486 nm after excitation at 410 nm. The developed method exhibited a good linear range from 0.5 µgmL-1 to 2.0 µgmL-1 with detection and quantification limits of 0.05 and 0.2 (µgmL-1), respectively. The profitable applicability of the developed method in spiked human plasma samples was demonstrated, achieving limit of detection below the previously levels reported by spectroscopic methods, allowing application of the developed method for selective determination of MBG in its tablets and spiked human plasma samples with good recovery.


Asunto(s)
Acetanilidas , Límite de Detección , Espectrometría de Fluorescencia , Tiazoles , Humanos , Tiazoles/sangre , Tiazoles/química , Acetanilidas/sangre , Acetanilidas/química , Espectrometría de Fluorescencia/métodos , Reproducibilidad de los Resultados
2.
Spectrochim Acta A Mol Biomol Spectrosc ; 319: 124521, 2024 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-38830329

RESUMEN

The USFDA recently approved mirabegron, a novel once-daily ß-3 adrenoceptor agonist for oral administration, as a transformative treatment for overactive bladder. Despite the existence of numerous analytical methods for the assay and bioanalysis of mirabegron, it's perplexing that none have explored the domain of microwave-assisted sensitive spectrofluorimetric method for mirabegron estimation, even after extensive literature review. Adding to the enigma is the insistence of current analytical methods on using expensive and harmful organic solvents, posing a threat to marine life and the broader environment. Recently, the white analytical chemistry approach has been introduced to develop analytical methods that are cost-effective, environmentally friendly, and user-friendly. Consequently, a white analytical chemistry-based, sensitive, and eco-friendly spectrofluorimetric estimation of mirabegron has been initiated, using 4-Chloro-7-nitrobenzofurazan as a fluorescent biosensing probe. The development of this robust method involved a series of experiments designed to minimize solvent and time wastage. Through a combination of fractional factorial and Box-Behnken designs, researchers identified the critical variables and optimized the method to perfection. This method was validated according to the stringent ICH Q2 (R2) and USFDA guidelines, ensuring its reliability and accuracy. Once approved, this sensitive spectrofluorimetric method was tested, accurately estimating mirabegron levels in commercial formulations and rat plasma samples. To further enrich the study, a comprehensive evaluation of existing analytical methods was conducted alongside the proposed spectrofluorimetric method, using advanced tools like the AGREE calculator, GAPI software, and RGB model to assess their eco-friendliness and effectiveness in mirabegron estimation.


Asunto(s)
Acetanilidas , Colorantes Fluorescentes , Microondas , Espectrometría de Fluorescencia , Tiazoles , Tiazoles/química , Tiazoles/sangre , Tiazoles/análisis , Acetanilidas/análisis , Acetanilidas/sangre , Acetanilidas/química , Animales , Colorantes Fluorescentes/química , Espectrometría de Fluorescencia/métodos , Técnicas Biosensibles/métodos , Tecnología Química Verde/métodos , Reproducibilidad de los Resultados , Ratas , Límite de Detección , Masculino
3.
Clin Pharmacol Ther ; 116(3): 736-746, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38369608

RESUMEN

This was an open-label, single-dose, phase I study to characterize the pharmacokinetics (PKs), pharmacodynamics (PDs), and safety of edoxaban in pediatric subjects from birth to 18 years at risk for venous thromboembolism (VTE). Children requiring anticoagulant therapy were enrolled into 5 age cohorts (0 to < 6 months (N = 12), 0.5 to < 2 years (N = 13), 2 to < 6 years (N = 13), 6 to < 12 years (N = 13), and 12 to < 18 years (N = 15)) receiving tablet or oral suspension of edoxaban at doses expected to be equivalent to 30 or 60 mg once daily (q.d.) in adult subjects with VTE. Sixty-six pediatric subjects were enrolled and completed the study. Edoxaban plasma concentration peaked between 1 and 3 hours and declined rapidly until 4-8 hours. The range of mean total apparent clearance across 5 age cohorts at low and high doses was 0.47 to 1.11 L/h/kg. The ranges of mean volume of central compartment and apparent peripheral volume were 2.31 to 3.59 L/kg and 1.92 to 4.14 L/kg, respectively. Across all age groups, the estimated median exposures were within the 0.5- to 1.5-fold of the median area under the plasma drug concentration-time curve (AUC) in adult subjects receiving corresponding doses (30 mg q.d. for low dose and 60 mg q.d. for high dose). In all age groups, PD parameters (prothrombin time, activated partial thromboplastin time, and anti-Factor Xa activity) showed a linear PK-PD relationship and were in line with previous adult data. The results support further evaluation of the pediatric doses in larger pivotal trials.


Asunto(s)
Inhibidores del Factor Xa , Piridinas , Tiazoles , Tromboembolia Venosa , Humanos , Piridinas/farmacocinética , Piridinas/efectos adversos , Piridinas/administración & dosificación , Piridinas/sangre , Niño , Tiazoles/farmacocinética , Tiazoles/efectos adversos , Tiazoles/administración & dosificación , Tiazoles/sangre , Preescolar , Adolescente , Lactante , Masculino , Femenino , Recién Nacido , Tromboembolia Venosa/tratamiento farmacológico , Inhibidores del Factor Xa/farmacocinética , Inhibidores del Factor Xa/efectos adversos , Inhibidores del Factor Xa/administración & dosificación , Relación Dosis-Respuesta a Droga , Factores de Edad , Administración Oral , Área Bajo la Curva
4.
Spectrochim Acta A Mol Biomol Spectrosc ; 318: 124515, 2024 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-38810435

RESUMEN

Mirabegron (MRB) is a ß3-adrenoceptor agonist used for managing overactive bladder syndrome. A cost-effective, environmentally friendly, and highly sensitive spectrofluorimetric method was suggested to serve the purpose of quantifying MRB in its pure state, pharmaceutical tablets, spiked human plasma and urine, and testing content uniformity. In the present study, ninhydrin and phenylacetaldehyde react with the amino group moiety of MRB in Teorell-Stenhagen buffer (pH 7.5) to generate a strongly fluorescent diaryl pyrrolone compound that emits fluorescence at a wavelength of 477 nm upon excitation at 385 nm. The obtained calibration curve showed a linear relationship with a high correlation coefficient (r = 0.9997) in the concentration range of 0.25 to 5.0 µg mL-1. Limits of detection (LOD) and quantitation (LOQ) were 0.082 and 0.248 µg mL-1 respectively. The procedure was verified in accordance with the ICH guidelines. The suggested approach could be utilized for the selective analysis of MRB in its pharmaceuticals, either containing a single drug or co-formulated with solifenacin succinate. The greenness of the suggested method was confirmed using different green analytical metrics.


Asunto(s)
Acetanilidas , Límite de Detección , Ninhidrina , Espectrometría de Fluorescencia , Tiazoles , Humanos , Ninhidrina/química , Espectrometría de Fluorescencia/métodos , Acetanilidas/orina , Acetanilidas/sangre , Acetanilidas/química , Tiazoles/química , Tiazoles/orina , Tiazoles/sangre , Pirroles/química , Colorantes Fluorescentes/química , Colorantes Fluorescentes/síntesis química , Comprimidos , Acetaldehído/análogos & derivados
5.
Clin Pharmacol Drug Dev ; 13(7): 748-754, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38573189

RESUMEN

Nitazoxanide (NTZ) is an effective antiparasitic drug with potent antiviral and antimicrobial activity. This randomized, open-label, 2-sequence, 2-period crossover trial was designed to evaluate the bioequivalence (BE) of the NTZ dry suspension in healthy subjects and investigated the effect of food intake on the pharmacokinetic (PK) properties of tizoxanide (an active metabolite of NTZ, TIZ). Sixty healthy Chinese subjects were enrolled and received a single dose of 500 mg/25 mL of preparations on days 1 and 4 under overnight fasting or fed conditions, respectively. The plasma concentration of TIZ was determined using high-performance liquid chromatography/tandem mass spectrometry. PK parameters were calculated using WinNonlin 8.2 and BE was evaluated using SAS 9.4. The 90% confidence intervals for the geometric mean ratio (test/reference) of maximum concentration (Cmax), the area under the curve from time 0 to the time of the last quantifiable concentration (AUC0-t), and the area under the curve from time 0 to extrapolation to infinity (AUC0-∞) were all within the equivalent interval of 80%-125%, compliant with BE requirements. In comparison with fasting, on taking the reference and test preparations of the NTZ dry suspension after a meal, the AUC0-t increased by 48.9% and 47.3%, respectively, the AUC0-∞ increased by 48.4% and 48.3%, respectively, and the post-meal Tmax was prolonged by 1.8-2 hours. Our results demonstrate that the test and reference preparations were bioequivalent. High-fat meals significantly improve the degree of drug absorption and delay the rate of drug absorption.


Asunto(s)
Área Bajo la Curva , Estudios Cruzados , Interacciones Alimento-Droga , Voluntarios Sanos , Nitrocompuestos , Suspensiones , Equivalencia Terapéutica , Tiazoles , Humanos , Masculino , Adulto , Adulto Joven , Administración Oral , Tiazoles/farmacocinética , Tiazoles/administración & dosificación , Tiazoles/sangre , Femenino , Nitrocompuestos/farmacocinética , Nitrocompuestos/administración & dosificación , Ayuno , Antiparasitarios/farmacocinética , Antiparasitarios/administración & dosificación , Antiparasitarios/sangre , Espectrometría de Masas en Tándem , Cromatografía Líquida de Alta Presión
6.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 65(2): 141-148, Feb. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-990335

RESUMEN

SUMMARY Mirabegron is a kind of β3 adrenergic receptor agonist which is an effective drug for the treatment of overactive bladder. In this research, a UPLC-MS/MS method is developed and validated for the study of mirabegron pharmacokinetic in rats. A protein precipitation method is applied for sample preparation with acetonitrile. m/z 397.3→379.6, m/z 326.4→121.0 for mirabegron, tolterodine (IS), respectively in the positive ion mode was performed for quantitation. The method is reliable and reproducible in our study (intra-day precision≤11.06%, inter-day precision≤11.43%) with concentration curves linear from 5 to 2500 ng/mL(R2>0.999). Stability studies demonstrated that mirabegron was stable under a variety of storage conditions. This method was successfully applied for determining mirabegron in rats after oral and intravenous administration.


RESUMO Mirabegron é um tipo de agonista do receptor adrenérgico beta 3 que demonstra eficácia no tratamento de bexiga hiperativa. Nesta pesquisa, o método UPLC-MS/MS é desenvolvido e validado para o estudo da farmacocinética mirabegron em ratos. Um método de precipitação de proteínas é aplicado para a preparação de amostras com acetonitrilo. 397.3 → 379.6 M / Z, M / Z 326.4 → 121.0 para mirabegron, tolterodina (IS), respectivamente, para o íon positivo foi realizado para quantificação. O método é fiável e reprodutível em nosso estudo (precisão intradia ≤ 11,06%; precisão entredia ≤ 11.43%), com curvas de concentração linear de 5 a 2 ng/ml (R2 > 0,999). Estudos de estabilidade demonstraram que mirabegron permanece estável sob uma variedade de condições de armazenamento. Este método foi aplicado com sucesso para a determinação de mirabegron em ratos após administração oral e intravenosa.


Asunto(s)
Animales , Masculino , Ratas , Tiazoles/farmacocinética , Agonistas de Receptores Adrenérgicos beta 3/farmacocinética , Acetanilidas/farmacocinética , Tiazoles/administración & dosificación , Tiazoles/sangre , Administración Oral , Reproducibilidad de los Resultados , Cromatografía Líquida de Alta Presión , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem , Agonistas de Receptores Adrenérgicos beta 3/administración & dosificación , Agonistas de Receptores Adrenérgicos beta 3/sangre , Administración Intravenosa , Acetanilidas/administración & dosificación , Acetanilidas/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA